Loading
Duke oncologist who led MOUNTAINEER, the trial that made tucatinib plus trastuzumab the first approved HER2-directed treatment for colorectal cancer.
John Strickler is a gastrointestinal medical oncologist at Duke Cancer Institute. He was first author of the 2023 Lancet Oncology report of MOUNTAINEER, the phase 2 trial in which tucatinib plus trastuzumab produced durable responses in chemotherapy-refractory HER2-positive, RAS wild-type metastatic colorectal cancer, leading to accelerated approval. He also led early work on sotorasib in KRAS G12C colorectal cancer and studies ctDNA to guide therapy.
| Title | Journal | Year |
|---|---|---|
| MOUNTAINEER: tucatinib plus trastuzumab for HER2-positive, RAS wild-type metastatic colorectal cancer | The Lancet Oncology | 2023 |
Shares Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER), HER2-amplified colorectal cancer, Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
Shares HER2-amplified colorectal cancer, Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
Shares Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
Shares Colorectal cancer and the tags colorectal, trialist.
Shares Colorectal cancer and the tags colorectal, trialist.
Shares Colorectal cancer and the tags colorectal, trialist.
Shares Colorectal cancer and the tags colorectal, trialist.
Shares Colorectal cancer and the tags colorectal, trialist.